Russell Greig, a former GlaxoSmithKline Plc executive, has been appointed independent chair of Cardior Pharmaceuticals GmbH which is developing non-coding RNA-based therapeutics for patients with cardiac diseases. At GSK, Dr Grieg worked in research and development and commercial operations. Most recently, he served as president of SR One, the company’s venture capital arm. Dr Greig graduated from the University of Manchester, UK, with a bachelor of science and PhD in biochemistry.
Cardior Pharmaceuticals announced the appointment on 6 April 2022.
Copyright 2022 Evernow Publishing Ltd